176 related articles for article (PubMed ID: 31037824)
1. A flexible parametric survival model for fitting time to event data in clinical trials.
Liao JJZ; Liu GF
Pharm Stat; 2019 Oct; 18(5):555-567. PubMed ID: 31037824
[TBL] [Abstract][Full Text] [Related]
2. Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses.
Cislo PR; Emir B; Cabrera J; Li B; Alemayehu D
Value Health; 2021 Nov; 24(11):1643-1650. PubMed ID: 34711365
[TBL] [Abstract][Full Text] [Related]
3. A hybrid approach to predicting events in clinical trials with time-to-event outcomes.
Fang L; Su Z
Contemp Clin Trials; 2011 Sep; 32(5):755-9. PubMed ID: 21645644
[TBL] [Abstract][Full Text] [Related]
4. Covariate-adjusted non-parametric survival curve estimation.
Jiang H; Symanowski J; Qu Y; Ni X; Wang Y
Stat Med; 2011 May; 30(11):1243-53. PubMed ID: 21344475
[TBL] [Abstract][Full Text] [Related]
5. A Weibull multi-state model for the dependence of progression-free survival and overall survival.
Li Y; Zhang Q
Stat Med; 2015 Jul; 34(17):2497-513. PubMed ID: 25865438
[TBL] [Abstract][Full Text] [Related]
6. Improved survival modeling in cancer research using a reduced piecewise exponential approach.
Han G; Schell MJ; Kim J
Stat Med; 2014 Jan; 33(1):59-73. PubMed ID: 23900779
[TBL] [Abstract][Full Text] [Related]
7. Weibull prediction of event times in clinical trials.
Ying GS; Heitjan DF
Pharm Stat; 2008; 7(2):107-20. PubMed ID: 17377932
[TBL] [Abstract][Full Text] [Related]
8. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
9. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
[TBL] [Abstract][Full Text] [Related]
10. Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study.
Beca JM; Chan KKW; Naimark DMJ; Pechlivanoglou P
BMC Med Res Methodol; 2021 Dec; 21(1):282. PubMed ID: 34922454
[TBL] [Abstract][Full Text] [Related]
11. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.
Gelber RD; Goldhirsch A; Cole BF
Control Clin Trials; 1993 Dec; 14(6):485-99. PubMed ID: 8119064
[TBL] [Abstract][Full Text] [Related]
12. A bivariate power generalized Weibull distribution: A flexible parametric model for survival analysis.
Jones MC; Noufaily A; Burke K
Stat Methods Med Res; 2020 Aug; 29(8):2295-2306. PubMed ID: 31840558
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis in public health research.
Lee ET; Go OT
Annu Rev Public Health; 1997; 18():105-34. PubMed ID: 9143714
[TBL] [Abstract][Full Text] [Related]
14. Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysis.
Crowther MJ; Look MP; Riley RD
Stat Med; 2014 Sep; 33(22):3844-58. PubMed ID: 24789760
[TBL] [Abstract][Full Text] [Related]
15. Application of a hazard-based visual predictive check to evaluate parametric hazard models.
Huh Y; Hutmacher MM
J Pharmacokinet Pharmacodyn; 2016 Feb; 43(1):57-71. PubMed ID: 26563504
[TBL] [Abstract][Full Text] [Related]
16. Modelling survival in hepatocellular carcinoma.
Muszbek N; Kreif N; Valderrama A; Benedict A; Ishak J; Ross P
Curr Med Res Opin; 2012 Jul; 28(7):1141-53. PubMed ID: 22563794
[TBL] [Abstract][Full Text] [Related]
17. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
[TBL] [Abstract][Full Text] [Related]
18. Power and sample size for randomized phase III survival trials under the Weibull model.
Wu J
J Biopharm Stat; 2015; 25(1):16-28. PubMed ID: 24895942
[TBL] [Abstract][Full Text] [Related]
19. Parametric bootstrap for testing model fitting in the proportional hazards framework: an application to the survival analysis of Bruna dels Pirineus beef calves.
Casellas J; Tarrés J; Piedrafita J; Varona L
J Anim Sci; 2006 Oct; 84(10):2609-16. PubMed ID: 16971560
[TBL] [Abstract][Full Text] [Related]
20. [Application of alternative parametric models for the survival analysis of cancer patients].
Valencia-Orozco A; Parra-Lara LG; Martínez JW; Tovar-Cuevas JR
Rev Peru Med Exp Salud Publica; 2019; 36(2):341-348. PubMed ID: 31460650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
